

# New Glaucoma Care Restriction: IOP Targets and Treatment Access

Written by The Life Science Feed Editorial Team · Published 28 June 2026 · Edited by Mara Voss

The management of glaucoma, a leading cause of irreversible blindness, relies fundamentally on the reduction of intraocular pressure (IOP) to preserve visual field. A recent policy adjustment regarding the availability of specific prostaglandin analogues for first-line therapy introduces a clinical dilemma, potentially narrowing treatment choices for general practitioners and specialists alike.

## KEY TAKEAWAYS

- **The Pivot:** A new restriction limits the first-line use of certain prostaglandin analogues for glaucoma, potentially impacting established treatment algorithms.
- **The Data:** Prostaglandin analogues consistently demonstrate IOP reduction of 25-33% from baseline, with some achieving 30-35% reductions in specific patient populations.
- **The Action:** Clinicians should re-evaluate their initial treatment strategies for open-angle glaucoma and ocular hypertension, considering the implications for IOP target attainment and patient adherence.

Glaucoma encompasses a group of optic neuropathies characterised by progressive retinal ganglion cell death and corresponding visual field loss. Elevated intraocular pressure (IOP) is the primary modifiable risk factor, and its reduction remains the cornerstone of therapeutic intervention. The goal of treatment is to lower IOP to a level that prevents further optic nerve damage, often referred to as the 'target IOP'. This target is individualised based on factors such as baseline IOP, severity of optic nerve damage, visual field status, and patient age. For many patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT), the initial target IOP reduction is typically 25-30% from baseline. The European Glaucoma Society guidelines, for instance, recommend an initial IOP reduction of at least 20% for early to moderate glaucoma, with more aggressive targets for advanced disease.<sup>1</sup>

Pharmacological therapy for glaucoma primarily involves topical eye drops that either decrease aqueous humour production or increase aqueous humour outflow. Prostaglandin analogues (PGAs), such as latanoprost, travoprost, bimatoprost, and tafluprost, are widely recognised as the most effective and generally well-tolerated first-line agents for reducing IOP. Their mechanism of action involves increasing uveoscleral outflow, leading to sustained IOP reduction over a 24-hour period. Clinical trials have consistently demonstrated their efficacy. For example, a meta-analysis comparing various PGAs reported mean IOP reductions ranging from 25% to 33% from baseline, with some studies showing reductions of up to 35% in specific cohorts.<sup>2</sup> The once-daily dosing regimen of PGAs also contributes to better patient adherence compared to medications requiring multiple daily applications, a critical factor in chronic disease management.<sup>3</sup>

The recent policy change restricts the first-line prescribing of certain prostaglandin analogues, specifically those that

are not generic latanoprost. This decision mandates that clinicians initiate treatment with generic latanoprost before considering other PGA options or alternative drug classes. While generic latanoprost is an effective agent, this restriction overlooks the nuanced differences in efficacy, tolerability, and patient response observed among the various PGAs. For instance, travoprost has demonstrated a slightly greater IOP reduction in some comparative studies, particularly in patients with higher baseline IOPs. A randomised controlled trial comparing travoprost 0.004% with latanoprost 0.005% found that travoprost achieved a mean diurnal IOP reduction of 8.1 mmHg from a baseline of 25.3 mmHg, compared to 7.2 mmHg for latanoprost from a baseline of 25.1 mmHg, representing a statistically significant difference ( $P=0.004$ ).<sup>4</sup> Similarly, bimatoprost 0.03% has been shown to provide superior IOP lowering compared to latanoprost 0.005% in several head-to-head trials, with one study reporting a mean IOP reduction of 8.3 mmHg for bimatoprost versus 7.0 mmHg for latanoprost ( $P0.001$ ).<sup>5</sup> These differences, while seemingly small, can be clinically meaningful for patients requiring aggressive IOP lowering to prevent disease progression.

Furthermore, patient tolerability and response to specific PGAs can vary. Ocular surface disease, including dry eye and conjunctival hyperaemia, is a common comorbidity in glaucoma patients and can be exacerbated by topical medications. While PGAs are generally well-tolerated, individual patients may experience different adverse effect profiles with different agents. For example, some patients may tolerate one PGA better than another due to variations in preservative content or specific molecular structure. The restriction to a single generic option as first-line therapy removes the clinician's ability to select the most appropriate PGA based on individual patient characteristics, potential for adverse effects, and the specific IOP target required. This could lead to a delay in achieving target IOP, necessitating earlier escalation to combination therapy or surgical intervention, which carry their own risks and costs.<sup>6</sup>

## Implications for Clinical Practice and Patient Outcomes

The immediate consequence of this policy is that clinicians must now navigate a more rigid treatment pathway. For patients who may not achieve their target IOP with generic latanoprost, or who experience intolerable side effects, a switch to another PGA or a different class of medication will be required. This sequential approach introduces additional clinic visits, potential delays in optimal IOP control, and increased patient anxiety. Each medication switch requires a washout period or careful monitoring to assess the new agent's efficacy, prolonging the time until stable IOP is achieved. This is particularly concerning for patients with advanced glaucoma or rapidly progressing disease, where timely and effective IOP reduction is paramount to preserving vision.<sup>7</sup>

The long-term implications for patient outcomes are also a concern. Suboptimal IOP control, even for short periods, can contribute to further optic nerve damage and visual field loss. A study investigating the impact of IOP fluctuation on glaucoma progression found that greater variability in IOP was associated with a higher risk of visual field deterioration, independent of mean IOP.<sup>8</sup> By limiting initial treatment choices, the policy may inadvertently increase the likelihood of IOP fluctuations or delays in achieving stable target IOP, potentially accelerating disease progression in a subset of patients. Moreover, the restriction may lead to increased prescribing of combination therapies earlier in the treatment algorithm, as clinicians seek to achieve target IOP when monotherapy with generic latanoprost proves insufficient. While combination therapies are effective, they often involve higher costs, increased complexity of dosing regimens, and a greater likelihood of adverse effects, all of which can negatively impact patient adherence.<sup>9</sup>

From an economic perspective, the rationale behind such a policy is often cost containment. Generic latanoprost is typically less expensive than branded PGAs or other generic PGAs. However, the potential for increased healthcare

costs due to more frequent clinic visits, medication switches, earlier use of more expensive combination therapies, or even the long-term costs associated with managing advanced glaucoma (e.g., low vision services, surgical interventions) must be considered. A comprehensive cost-effectiveness analysis would need to account for these downstream effects to determine the true economic impact of such a restrictive policy. The initial cost saving on medication may be offset by increased costs elsewhere in the patient care pathway.<sup>10</sup>

The policy also raises questions about the balance between cost-effectiveness and clinical autonomy. Clinicians, based on their expertise and understanding of individual patient needs, are best positioned to select the most appropriate initial therapy. Restricting this choice to a single generic option, without clear clinical justification based on superior efficacy or safety of that specific agent across all patient populations, undermines evidence-based medicine and personalised care. While generic medications play a vital role in healthcare affordability, blanket restrictions that do not account for individual patient variability or the subtle but clinically relevant differences between agents within a drug class can have unintended negative consequences. The availability of multiple PGA options allows for tailoring treatment to optimise both efficacy and tolerability, thereby maximising the chances of long-term adherence and successful IOP control.<sup>11</sup> In conclusion, while generic latanoprost is an effective first-line agent for glaucoma, the new policy restricting initial PGA choice warrants a closer look. The potential for delayed target IOP attainment, increased patient burden due to medication switches, and the erosion of clinical autonomy in selecting the most appropriate initial therapy are significant concerns. Future evaluations of this policy should consider not only the immediate cost savings but also the broader impact on patient outcomes, healthcare resource utilisation, and the quality of glaucoma care.

#### CLINICAL IMPLICATIONS

The recent policy dictating generic latanoprost as the mandatory first-line prostaglandin analogue for glaucoma management is a concerning development. While cost-saving measures are understandable, this particular restriction risks undermining the nuanced approach required for effective glaucoma care. Clinicians are now forced into a 'one-size-fits-all' initial strategy, potentially delaying optimal IOP control for patients who might respond better to, or tolerate, another PGA. This isn't merely about brand versus generic; it's about the subtle but clinically relevant differences in efficacy and tolerability that exist even within a drug class, differences that allow for personalised medicine.

For patients, this could mean a prolonged period of trial and error, additional clinic visits, and the anxiety of unstable IOP before finding a truly effective treatment. The argument that all PGAs are equivalent for initial therapy ignores the evidence demonstrating marginal but significant differences in IOP lowering between agents like travoprost, bimatoprost, and latanoprost in certain populations. These differences, when compounded over years of treatment, can be critical in preventing irreversible vision loss. Furthermore, individual patient tolerability to preservatives or specific formulations can dictate adherence, and removing choice at the outset may inadvertently increase non-adherence rates.

This policy also raises questions about the role of guideline bodies and pharmaceutical companies. While generic manufacturers benefit from such mandates, the broader market for other effective PGAs could shrink, potentially stifling innovation or reducing competition. Guideline developers, such as the European Glaucoma Society, typically advocate for a range of first-line options based on evidence, not solely on cost. This restriction appears to prioritise immediate cost savings over the long-term clinical benefits of tailored therapy, potentially

leading to higher overall healthcare costs down the line if patients experience accelerated disease progression requiring more complex and expensive interventions.

#### EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

#### REFERENCES

1. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 5th ed. 2020. Available from: [www.eugs.org](http://www.eugs.org)
2. van der Valk R, Webers CAB, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a systematic review. *Ophthalmology*. 2005;112(7):1177-1185. doi:10.1016/j.ophtha.2005.01.042
3. Reardon G, Schwartz GF, Mozaffari E. Patient adherence to glaucoma therapy: a meta-analysis of published reports. *J Glaucoma*. 2011;20(8):460-469.
4. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. *Am J Ophthalmol*. 2001;132(4):472-484. doi:10.1016/s0002-9394(01)01177-1
5. Parrish RK, Herndon LW, Wilson MR, et al. Bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension: a 12-week randomised, double-masked, multicentre study. *Am J Ophthalmol*. 2003;135(5):688-693.
6. Stewart WC, Konstas AG, Nelson LA, et al. Meta-analysis of 24-hour intraocular pressure fluctuation with glaucoma medications. *J Ocul Pharmacol Ther*. 2007;23(4):345-352.
7. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the Early Manifest Glaucoma Trial. *Ophthalmology*. 2007;114(10):1965-1972. doi:10.1016/j.ophtha.2007.03.016
8. Caprioli J, Coleman AL. Intraocular pressure fluctuation and the progression of glaucoma. *J Glaucoma*. 2010;19(7):421-426.
9. Robin AL, Covert D. Adherence in glaucoma: a patient perspective. *J Ocul Pharmacol Ther*. 2005;21(6):447-452.
10. Traverso CE, Walt JG, Kelly SP, et al. The cost of glaucoma: a systematic review. *Eur J Ophthalmol*. 2005;15(6):663-677.
11. Friedman DS, Quigley HA, Gelb L, et al. The cost-effectiveness of screening for glaucoma. *Ophthalmology*. 2005;112(12):2124-2131.

#### LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

#### MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

#### FOLLOW THE LIFE SCIENCE FEED

**Instagram** @lifesciencefeed    **LinkedIn** [linkedin.com/company/thelifesciencefeed](https://www.linkedin.com/company/thelifesciencefeed)

[thelifesciencefeed.com](http://thelifesciencefeed.com)